Muthu Vaduganathan(@mvaduganathan) 's Twitter Profileg
Muthu Vaduganathan

@mvaduganathan

Cardiologist & Trialist @BrighamWomens @harvardmed | Section Ed @JACCJournals | AE #JACCHF | Podcast #DontMissABeat & #HFinFocus | Disclosures: https://t.co/BmQHCNyLml

ID:888976053951180801

linkhttps://connects.catalyst.harvard.edu/Profiles/display/Person/108817 calendar_today23-07-2017 04:16:22

5,3K Tweets

7,2K Followers

523 Following

Brendon Neuen(@brendonneuen) 's Twitter Profile Photo

Pooled data for bexagliflozin (FDA approved for type 2 diabetes in 2023), including data from the BEST trial (cardiovascular outcome trial, n~1700)

dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

account_circle
Brendon Neuen(@brendonneuen) 's Twitter Profile Photo

NUDGE-CKD

A *nationwide* Danish 🇩🇰 randomised trial from Tor Biering-Sørensen, MD, MSc, MPH, PhD & team

Can letters by increase uptake of guideline recommended kidney care (RASi, SGLT2i) in people with CKD?

- 2x2 design
- Patient level randomisation
- GP Cluster randomisation

account_circle
Ankeet S. Bhatt, MD, MBA(@ankeetbhatt) 's Twitter Profile Photo

are all around us. Leveraging 4 health using scalable, existing dissemination platforms may drive . In partnership with CPR Trials & CIRL Tor Biering-Sørensen, MD, MSc, MPH, PhD, we highlight NEJM Evidence the 🇩🇰 concept, a series of nationwide studies 4 health

#Nudges are all around us. Leveraging #behavorialsci 4 health using scalable, existing dissemination platforms may drive #pophealth. In partnership with @CIRL_DK @TorBiering, we highlight @NEJMEvidence the 🇩🇰 #NUDGEtrial concept, a series of nationwide #impsci studies 4 health
account_circle
Tor Biering-Sørensen, MD, MSc, MPH, PhD(@TorBiering) 's Twitter Profile Photo

Our most recent analysis from the NUDGE-FLU trial assessing the effect of NUDGES to increase flu vaccine uptake amongst DM patients just published in JAMA Open. Analysis lead by the brilliant Mats C. Højbjerg Lassen 👏

account_circle
Mats C. Højbjerg Lassen(@matslassen) 's Twitter Profile Photo

Excited to share our latest analysis from the NUDGE-FLU trial!

N=964870 👴🧓 ≥65 y (12.8% with DM🩸)

🖥️🛜 nudges ⬆️ flu vaccination rate 💉🦠 in those w/o DM but not in those with DM

Trials with nudges tailored for DM are needed!

Tor Biering-Sørensen, MD, MSc, MPH, PhD JAMA Network Open

Link below 👇

Excited to share our latest analysis from the NUDGE-FLU trial! N=964870 👴🧓 ≥65 y (12.8% with DM🩸) 🖥️🛜 nudges ⬆️ flu vaccination rate 💉🦠 in those w/o DM but not in those with DM Trials with nudges tailored for DM are needed! @TorBiering @JAMANetworkOpen Link below 👇
account_circle
HCPLive(@HCPLiveNews) 's Twitter Profile Photo

The latest research from the NUDGE-FLU trial provides insight into the effects of electronic nudges based on diabetes status.

hcplive.com/view/electroni…

The latest research from the NUDGE-FLU trial provides insight into the effects of electronic nudges based on diabetes status. hcplive.com/view/electroni… #Diabetes
account_circle
Alfonso Valle(@ValleAlfonso) 's Twitter Profile Photo

⚠️Heart failure, sleep apnea and dapagliflozin: -HF &

🎯worsening HF or CV☠️

📈prevalence of sleep apnea was 5.7% and 7.8% in HFrEF and HFmrEF/HFpEF, respectively

👉WHF/CV☠️ 16% with sleep apnea vs 10.6%-years in those without

💊dapagliflozin ⤵️ the risk of the…

⚠️Heart failure, sleep apnea and dapagliflozin: #DAPA-HF & #DELIVER 🎯worsening HF or CV☠️ 📈prevalence of sleep apnea was 5.7% and 7.8% in HFrEF and HFmrEF/HFpEF, respectively 👉WHF/CV☠️ 16% with sleep apnea vs 10.6%-years in those without 💊dapagliflozin ⤵️ the risk of the…
account_circle
Julia Seller(@JuliaSellerm) 's Twitter Profile Photo

5️⃣ Drugs in HF

🔷 PARAGLIDE ➕PARAGON

Sacubitril/valsartan ⬇️ CV and renal events in HFmrEF and HFpEF.

doi.org/10.1093/eurhea…

🔹 Beta-Blocker use and HFmrEF and HFpEF

jacc.org/doi/10.1016/j.…

5️⃣ Drugs in HF 🔷 PARAGLIDE ➕PARAGON Sacubitril/valsartan ⬇️ CV and renal events in HFmrEF and HFpEF. doi.org/10.1093/eurhea… 🔹 Beta-Blocker use and HFmrEF and HFpEF jacc.org/doi/10.1016/j.…
account_circle
Gregg Fonarow MD(@gcfmd) 's Twitter Profile Photo

Compared to ACEI+BB, treatment with disease-modifying quadruple ARNI+BB+MRA+SGLTi in eligible patients with HFrEF

➡️ additional years of overall survival

55 yo: 6.3 years
65 yo: 4.4 years
70 yo: 3.9 years
75 yo: 3.1 years
80 yo: 1.4 years

Not days, weeks, or months…

Years!

Compared to ACEI+BB, treatment with disease-modifying quadruple ARNI+BB+MRA+SGLTi in eligible patients with HFrEF ➡️ additional years of overall survival 55 yo: 6.3 years 65 yo: 4.4 years 70 yo: 3.9 years 75 yo: 3.1 years 80 yo: 1.4 years Not days, weeks, or months… Years!
account_circle
JASN_News(@JASN_News) 's Twitter Profile Photo

Strategies to enable persistent use of RAS blockade to improve outcomes in CKD have long been sought. This Podcast discusses a recent study that found SGLT2 inhibitors facilitate the use of RAS blockade in patients with albuminuric CKD bit.ly/JPOD0248

Strategies to enable persistent use of RAS blockade to improve outcomes in CKD have long been sought. This Podcast discusses a recent study that found SGLT2 inhibitors facilitate the use of RAS blockade in patients with albuminuric CKD bit.ly/JPOD0248
account_circle
Rajiv Agarwal MD, MS(@AgarwalRajivMD) 's Twitter Profile Photo

Let us stop calling spironolactone an aldosterone blocker or aldosterone antagonist. It is, but it also is not...read here: Blocking aldosterone or its receptor—what is the difference? - The Lancet
thelancet.com/journals/lance…

account_circle
Joseph Goldenberg, MD PhD(@JR_Goldenberg) 's Twitter Profile Photo

Better preserved myocardial energetics detected by non-invasive cardiac 31P MRS in HFrEF predicts future LVEF recovery, LV reverse remodeling, and clinical hard outcomes (cardiac death, LVAD, or transplant). Our paper just out in Circulation! ahajournals.org/doi/10.1161/CI…

account_circle
Ankeet S. Bhatt, MD, MBA(@ankeetbhatt) 's Twitter Profile Photo

Despite clear evidence of ⏬risk, pervasive gaps exist in reaching LDL-C goals. Excited to partner with American College of Cardiology to lead this 🌟new initiative🌟, in LDL-C screening, testing implementation approaches in >30,000 clinicians.
acc.org/About-ACC/Pres…

account_circle
George Mensah, MD(@NHLBI_Translate) 's Twitter Profile Photo

.JACC Journals: New. Open Access. Health estimates for the global, regional, and national burden and trends of and risks from 1990-2022 with data on risks. A joint effort of @NIH_NHLBI Institute for Health Metrics and Evaluation (IHME) JACC Journals
Read: bit.ly/3uZoDVW

.@JACCJournals: New. Open Access. Health estimates for the global, regional, and national burden and trends of #CVD and risks from 1990-2022 with data on #environmental #metabolic #behavioral risks. A joint effort of @NIH_NHLBI @IHME_UW @JACCJournals Read: bit.ly/3uZoDVW
account_circle
JASN_News(@JASN_News) 's Twitter Profile Photo

An analysis of 7 clinical trials suggests that clinical trials for kidney disease progression might attain increased statistical power at equivalent sample sizes by using a new hierarchical composite endpoint that prioritizes clinically important outcomes bit.ly/JASN0243

An analysis of 7 clinical trials suggests that clinical trials for kidney disease progression might attain increased statistical power at equivalent sample sizes by using a new hierarchical composite endpoint that prioritizes clinically important outcomes bit.ly/JASN0243
account_circle
Deidra Crews, MD, ScM, FASN, MACP(@DrDeidraCrews) 's Twitter Profile Photo

Quite an honor to speak today at Cardiovascular Grand Rounds Brigham and Women's Hospital

A definite highlight was having lunch with some BWH Cardiology fellows. Future is bright for cardio-kidney collaborations!

Quite an honor to speak today at Cardiovascular Grand Rounds @BrighamWomens A definite highlight was having lunch with some BWH Cardiology fellows. Future is bright for cardio-kidney collaborations!
account_circle